Trial of Screening for ALOA-IgG AtheroAbzyme Test

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 100 participants.

Also called NCT01272986

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01272986
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Lebanon (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01272986. Non-randomized; no masking; primary purpose diagnostic. Start 2011-01 (registry gives no type); primary completion 2011-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial of Screening for ALOA-IgG AtheroAbzyme Test
Acronym
OP512011
Condition
Myocardial Ischemia
Condition
Acute Coronary Syndrome
Intervention (Device)
ALOA IgG-Elisa
Intervention (Device)
ALOA IgG-AtheroAbzyme
Lead sponsor
Omicron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01272986
Content hash
0a74486471cf4a94a3570604c1be864c33693fc759abcaa92854eb3edf2e39aa